Chronic lymphocytic leukaemia, first treatment

aka Treatment-naive CLL, Front-line CLL, Previously untreated CLL, First-line CLL therapy

Chronic lymphocytic leukaemia is treated only when it causes problems, and chemotherapy has gone. The first treatment is now either a BTK inhibitor taken indefinitely or a one-year course of venetoclax with obinutuzumab (CLL14), and the two can be combined for a fixed course.

Part ofChronic lymphocytic leukaemia

Diagnosis needs 5 x 10^9/L clonal B cells with the typical CD5, CD19, CD23 phenotype; treatment starts only for iwCLL indications (symptoms, progressive anaemia or thrombocytopenia, bulky or fast-growing disease), because early treatment, even with ibrutinib in CLL12, has not lengthened life. Before the first treatment, every patient has FISH and sequencing for del(17p) and TP53 mutation and testing of IGHV mutational status, since these decide the regimen: TP53-aberrant disease does not respond durably to chemotherapy, and unmutated IGHV disease relapses early after it.

Two families of drugs replaced chemoimmunotherapy between 2014 and 2023. Continuous BTK inhibitors, ibrutinib and then the better-tolerated acalabrutinib (ELEVATE-TN, versus chlorambucil-obinutuzumab: median progression-free survival not reached at six years against 27.8 months) and zanubrutinib (SEQUOIA, versus bendamustine-rituximab, hazard ratio 0.42), control the disease for years but must be taken indefinitely and carry atrial fibrillation, bleeding and hypertension risks. Fixed-duration venetoclax with obinutuzumab for 12 months (CLL14, versus chlorambucil-obinutuzumab in older unfit patients: six-year progression-free survival 53.1 percent versus 21.7 percent, hazard ratio 0.40) gives most patients undetectable MRD and years off treatment; CLL13/GAIA confirmed the same in fit patients, where venetoclax-obinutuzumab and venetoclax-obinutuzumab-ibrutinib beat fludarabine-based chemoimmunotherapy (five-year progression-free survival 69.8 and 81.3 percent against 50.7 percent).

The third option is an all-oral fixed-duration doublet: ibrutinib-venetoclax (GLOW in older patients, hazard ratio 0.216 for progression; CAPTIVATE; and the UK FLAIR trial with MRD-guided duration) and acalabrutinib-venetoclax with or without obinutuzumab (AMPLIFY, 2025), which in 2026 joined the approved first-line options. Choice now turns on comorbidity, TP53 status (continuous BTK inhibitor favoured), patient preference for a finite course, drug interactions and cost; non-covalent BTK inhibitors, BTK degraders, sonrotoclax and MRD-guided stopping are in first-line trials.

State of the art

Chemoimmunotherapy has been displaced by BTK inhibitors and venetoclax-based fixed-duration regimens for almost every patient.
One year of venetoclax-obinutuzumab keeps half of older patients progression-free at six years.
All-oral fixed-duration doublets and MRD-guided duration are the current direction.

Red cards

From the labels and guidelines behind the standard of care. Your team's thresholds win.

Emergency services now
Bleeding or bruising
Bleeding that will not stop, black or bloody stools, or unexplained bruising when platelets are expected to be low.
Bendamustine Chlorambucil Cyclophosphamide source
Emergency services now
Major bleeding
Blood in stool or urine, vomiting blood, a bleed that will not stop, or a severe headache; fatal bleeding events have occurred and the labels advise considering the risk around surgery and with blood thinners.
Acalabrutinib Ibrutinib Zanubrutinib source
Emergency services now
Tumour lysis syndrome
Nausea, vomiting, muscle cramps, palpitations, seizures, confusion or passing much less urine in the first days of a new dose; the label requires hydration, anti-hyperuricaemic drugs and blood tests around each ramp-up step.
Venetoclax source
Check before combining
Food and drink: Ibrutinib
Avoid grapefruit and Seville oranges.
Ibrutinib source
Check before combining
Food and drink: Venetoclax
Take with a meal and water. Avoid grapefruit, Seville oranges and starfruit.
Venetoclax source
Check before combining
Heart rhythm (QT): Ibrutinib
Possible QT prolongation. Check ECG and electrolytes; review other QT-prolonging drugs.
Ibrutinib source

See all on the product pages:Acalabrutinib Bendamustine Chlorambucil Cyclophosphamide Ibrutinib Venetoclax Zanubrutinib·Printable cards in the navigator

Anatomy and lymph node drainage

Bone marrow, lymph nodes and spleen: subsites and node stations · wireframe schematic, not to scale

Organ atlas →

Leukaemias, myeloma and MDS live in the marrow and blood; lymphomas grow in lymph nodes and spleen. The node stations are the disease map, not a route of spread, and staging counts them.

Subsites

Bone marrow (leukaemia, MDS, MPN, myeloma)Treatment-naive CLL without del(17p) or TP53 mutation, IGHV mutated · Treatment-naive CLL, IGHV unmutated · Treatment-naive CLL with del(17p) or TP53 mutation (continuous BTK inhibitor favoured) · Fit patients starting first treatment (CLL13, AMPLIFY)
Lymph node germinal centre (lymphomas)
Spleen
Blood (leukaemic phase)Treatment-naive CLL without del(17p) or TP53 mutation, IGHV mutated · Treatment-naive CLL, IGHV unmutated · Treatment-naive CLL with del(17p) or TP53 mutation (continuous BTK inhibitor favoured) · Older or unfit patients starting first treatment (CLL14, GLOW) · Fit patients starting first treatment (CLL13, AMPLIFY) · Early-stage CLL under watch and wait
Lytic bone lesions (myeloma)
Skin and extranodal sites

Regional lymph nodes

cervical
axillary
mediastinal
para-aortic and mesenteric
inguinal

In lymphoma the node stations are the disease itself; staging (Ann Arbor / Lugano) counts how many regions and sides of the diaphragm are involved.

Same organ: Marginal zone lymphoma, Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome), Primary mediastinal (thymic) large B-cell lymphoma, Leukaemia (all types), Acute myeloid leukaemia, Acute lymphoblastic leukaemia, Chronic lymphocytic leukaemia, Chronic myeloid leukaemia (CML), Diffuse large B-cell lymphoma, Follicular lymphoma, Hodgkin lymphoma, Mantle cell lymphoma, Multiple myeloma, Non-Hodgkin lymphoma (all types), Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Polycythaemia vera (PV), Essential thrombocythaemia (ET), Waldenström macroglobulinaemia, Hairy cell leukaemia, Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma), Blastic plasmacytoid dendritic cell neoplasm (BPDCN), Burkitt lymphoma, HIV-associated (AIDS-related) lymphomas, Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms, Systemic mastocytosis, Erdheim-Chester disease, Rosai-Dorfman disease and other histiocytic neoplasms, Langerhans cell histiocytosis (LCH), Post-transplant lymphoproliferative disorder (PTLD), FLT3-mutated acute myeloid leukaemia, IDH1- and IDH2-mutated acute myeloid leukaemia, NPM1-mutated and KMT2A-rearranged acute myeloid leukaemia, Secondary and therapy-related acute myeloid leukaemia, Acute promyelocytic leukaemia, Acute myeloid leukaemia in older or unfit patients, Smouldering multiple myeloma, Newly diagnosed multiple myeloma, transplant-eligible, Newly diagnosed multiple myeloma, transplant-ineligible, Relapsed or refractory multiple myeloma, Plasma cell leukaemia, Lower-risk myelodysplastic syndromes, Higher-risk myelodysplastic syndromes, Relapsed or refractory chronic lymphocytic leukaemia, Richter transformation of chronic lymphocytic leukaemia, Chronic myeloid leukaemia, chronic phase, Chronic myeloid leukaemia, accelerated and blast phase, Primary myelofibrosis

Who gets it and what has changed

Chronic lymphocytic leukaemia is the commonest adult leukaemia in Western countries, with a median age at diagnosis of about 70; a third of patients never need treatment, and the rest start it when the disease causes symptoms, cytopenias or bulky nodes.

Group

haematologic

Cases by country

Cases by country · GLOBOCAN 2022

All countries →

No country-level case numbers. This cancer is not mapped to a GLOBOCAN site.

Standard of care

4top

Lines of therapy by subgroup →Staging and risk scores →

Decisions you may face

3 with more than one option · full decision page →

One section per setting: the options named, what each is for, the trials behind them, the recorded trade-offs and the questions to ask.

Asymptomatic early-stage disease First treatment, fixed duration4 First treatment, continuous3 Chemoimmunotherapy5

Asymptomatic early-stage disease

Watch and wait with counts every three to twelve months; treat only on iwCLL indications.

NCCN Guidelines: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Flow cytometry (immunophenotyping)IGHV mutational status del(17p) / TP53 aberration in CLL Cytogenetics and FISH

First treatment, fixed duration

Venetoclax plus obinutuzumab for 12 months (CLL14, CLL13); ibrutinib-venetoclax (GLOW, CAPTIVATE) or acalabrutinib-venetoclax with or without obinutuzumab (AMPLIFY) for fit patients.

NCCN Guidelines: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

VenetoclaxObinutuzumabCLL14 CLL13 / GAIAIbrutinibAcalabrutinibGLOW CAPTIVATE AMPLIFY Venetoclax + obinutuzumab (12 months)BTK inhibitor + venetoclax, fixed duration

First treatment, continuous

Acalabrutinib (ELEVATE-TN) or zanubrutinib (SEQUOIA) until progression, preferred for del(17p) or TP53-mutated disease; ibrutinib where the newer agents are unavailable.

NCCN Guidelines: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

AcalabrutinibZanubrutinibIbrutinibELEVATE-TN SEQUOIA Caution: ibrutinib in patients with cardiac risk

Chemoimmunotherapy

Fludarabine-cyclophosphamide-rituximab or bendamustine-rituximab only for IGHV-mutated disease without TP53 aberration where targeted drugs are unavailable; never for del(17p).

NCCN Guidelines: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

FludarabineCyclophosphamideRituximabBendamustineChlorambucilCaution: chemoimmunotherapy in del(17p)/TP53 CLL

Subtypes & biomarkers

top

Subtypes

Treatment-naive CLL without del (17p) or TP53 mutation, IGHV mutated
Treatment-naive CLL, IGHV unmutated
Treatment-naive CLL with del (17p) or TP53 mutation (continuous BTK inhibitor favoured)
Older or unfit patients starting first treatment (CLL14, GLOW)
Fit patients starting first treatment (CLL13, AMPLIFY)
Early-stage CLL under watch and wait

Biomarkers clinicians test

del (17p) by FISH and TP53 mutation
IGHV mutational status
CLL-IPI score
Beta-2 microglobulin
Complex karyotype
Undetectable MRD at end of fixed-duration therapy
Cardiac risk factors before BTK inhibitors

How often this target appears

History

7top

1952Chlorambucil introduced; the standard for forty years
Chlorambucil
2010CLL8: fludarabine-cyclophosphamide-rituximab lengthens life, the first regimen to do so
FludarabineRituximab
2014Ibrutinib approved for CLL; obinutuzumab-chlorambucil for unfit patients
IbrutinibObinutuzumab
2019CLL14: one year of venetoclax-obinutuzumab approved; ELEVATE-TN reports acalabrutinib
CLL14VenetoclaxELEVATE-TNAcalabrutinib
2022SEQUOIA: zanubrutinib beats bendamustine-rituximab; GLOW: ibrutinib-venetoclax approved in Europe
SEQUOIAZanubrutinibGLOW
2023CLL13: venetoclax-obinutuzumab beats chemoimmunotherapy in fit patients
CLL13 / GAIA
2025AMPLIFY: acalabrutinib-venetoclax fixed duration in fit patients
AMPLIFYAcalabrutinibVenetoclax

What changed

18top

Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.

All 18 changes by month →

FollowWatch this cancer and Saved shows what changed since you last looked.Follow by feed

In development

7top

What is in development for Chronic lymphocytic leukaemia, first treatment, drawn from the whole corpus: 17 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.

Drugs in phase 3 · 1

Phase 3Small-molecule non-covalent BTK inhibitor

Nemtabrutinib

Trials under way · 3

CELESTIAL-TNCLL · phase 3 · BeOne (BeiGene)
CaDAnCe-304 · phase 3 · BeOne (BeiGene)
BELLWAVE-011 · phase 3 · Merck

Trials reported · 7

AMPLIFY · phase 3 · 2024 · positive
CAPTIVATE · phase 2 · 2021 · positive
CLL13 / GAIA · phase 3 · 2023 · positive
CLL14 · phase 3 · 2019 · positive
ELEVATE-TN · phase 3 · 2019 · positive
GLOW · phase 3 · 2021 · positive
SEQUOIA · phase 3 · 2022 · positive

Combinations being explored · 4

BTK inhibitor + venetoclax, fixed duration Caution: chemoimmunotherapy in del(17p)/TP53 CLL Caution: ibrutinib in patients with cardiac risk Venetoclax + obinutuzumab (12 months)

Ideas not yet in a trial · 2

MRD-guided treatment duration in CLL BTK degraders to pre-empt resistance in frontline CLL

Open problems and what is being done

Continuous BTK inhibitor or fixed-duration venetoclax first: no head-to-head survival data.
Whether MRD should decide how long fixed-duration therapy lasts.
What is being done about this
Recurrence and residual disease
and how the field plans to fix it →
Available now
Multiparameter flow cytometry MRDStandard of care
In trials
Nothing recorded yet.
Ideas and roadmaps
MRD-guided treatment duration in CLL
Also on OnCo: Treatment journeys · Survivorship planner.
Cardiac toxicity, cost and interactions of indefinite BTK inhibition in patients in their seventies and eighties.
What is being done about this
Side effects and quality of life
and how the field plans to fix it →
Available now
CyclophosphamideApproved
In trials
Nothing recorded yet.
Ideas and roadmaps
Nothing recorded yet.
Also on OnCo: Side effects by symptom · Immune-related side effects · Toxicity compare · Survivorship planner.

Trials

top

Trials recruiting now

Recruiting trials near you · live from ClinicalTrials.gov

Chronic lymphocytic leukaemia, first treatment

condition: Chronic lymphocytic leukemia, first treatment

Open on ClinicalTrials.gov →

within

Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.

Landmark trials

AMPLIFY BELLWAVE-011 CaDAnCe-304 CAPTIVATE CELESTIAL-TNCLL CLL13 / GAIA CLL14 ELEVATE-TN GLOW SEQUOIA

Expert centres

top

Where the expertise is

Expert centres

4 centres in 3 countries · 0 with a trial for this cancer on record · second-opinion finder →

Choose a region from the globe in the header to mark centres near you.

4 centres


Walter and Eliza Hall Institute of Medical Research Melbourne · research institute	Australia	none recorded	298	3,639	CRISPR functional genomics Patient-derived organoids	-
HOVON Rotterdam · consortium	Netherlands	none recorded	8	207	MRD / molecular residual disease testing	-
Northwell Health Cancer Institute New Hyde Park, NY · hospital	United States	none recorded	not matched	-	CAR-T cell therapy	-
The Ohio State University Comprehensive Cancer Center, James Cancer Hospital and Solove Research Institute Columbus, OH · cancer center	United States	NCI comprehensive	not matched	-	Small-molecule kinase inhibitors Proton therapy Proton therapy machines: cyclotrons, synchrotrons and single-room systems	-

These are the things we can measure; they are not a ranking of quality. Each column is a field on the institution record or a count over what OnCo has linked; a centre that treats many patients with Chronic lymphocytic leukaemia, first treatment but is thinly recorded here will look small.

Not known: OnCo holds no case-volume or outcome figures for centres, so none are shown. Where a national audit or registry publishes them, the centre's page links to it. Default order: Newsweek rank, then trials for this cancer, then research output.

Seeking a second opinion: ask your oncologist for a referral to a high-volume centre; most accept records and pathology by mail or telehealth. In the US, use the NCI's Find a Cancer Center tool or the nonprofit Cancer Commons, which navigates options for advanced cancers at no cost. The second-opinion finder explains how referral works in your country.

Questions to ask

top

Bring to your appointment

Questions to ask your oncologist about Chronic lymphocytic leukaemia, first treatment

Generated from this cancer's standard of care, biomarkers, and pipeline · 18 questions

Newly diagnosed

What is my exact diagnosis, stage, and grade, and which tests established them?
Why: Everything else follows from an accurate stage and subtype.
Which biomarkers have been tested on my tumour (for example delby FISH and TP53 mutation, IGHV mutational status, CLL-IPI score, Beta-2 microglobulin, Complex karyotype), and what were the results?
Why: These results decide eligibility for targeted therapy, immunotherapy, and trials.
Which subtype is my cancer, and does that change the recommended treatment?
Why: Recognised subtypes for this cancer include Treatment-naive CLL without delor TP53 mutation, IGHV mutated, Treatment-naive CLL, IGHV unmutated, Treatment-naive CLL with delor TP53 mutation.
Is germline (inherited) genetic testing recommended for me or my family?
Why: Inherited variants can change treatment and matter for relatives.

Asymptomatic early-stage disease

For my situation (asymptomatic early-stage disease), which of the standard options do you recommend and why?
Why: Guideline options include: Watch and wait with counts every three to twelve months; treat only on iwCLL indications.

First treatment, fixed duration

For my situation (first treatment, fixed duration), which of the standard options do you recommend and why?
Why: Guideline options include: Venetoclax plus obinutuzumab for 12 months (CLL14, CLL13); ibrutinib-venetoclax (GLOW, CAPTIVATE) or acalabrutinib-venetoclax with or without obinutuzumab (AMPLIFY) for fit patients.
Am I a candidate for Venetoclax, Obinutuzumab, Ibrutinib or related drugs, and what side effects should I expect?
Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
How do the results of CLL14 and CLL13 / GAIA apply to someone like me?
Why: Trial populations differ from individual patients; ask how closely you match.

First treatment, continuous

For my situation (first treatment, continuous), which of the standard options do you recommend and why?
Why: Guideline options include: Acalabrutinib (ELEVATE-TN) or zanubrutinib (SEQUOIA) until progression, preferred for del(17p) or TP53-mutated disease; ibrutinib where the newer agents are unavailable.
Am I a candidate for Acalabrutinib, Zanubrutinib, Ibrutinib, and what side effects should I expect?
Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
How do the results of ELEVATE-TN and SEQUOIA apply to someone like me?
Why: Trial populations differ from individual patients; ask how closely you match.

Chemoimmunotherapy

For my situation (chemoimmunotherapy), which of the standard options do you recommend and why?
Why: Guideline options include: Fludarabine-cyclophosphamide-rituximab or bendamustine-rituximab only for IGHV-mutated disease without TP53 aberration where targeted drugs are unavailable; never for del(17p).
Am I a candidate for Fludarabine, Cyclophosphamide, Rituximab or related drugs, and what side effects should I expect?
Why: Knowing the expected toxicities helps you plan work, family, and supportive care.

Any stage

Are there clinical trials I could join, for example of Sonrotoclax, Nemtabrutinib, CELESTIAL-TNCLL, CaDAnCe-304?
Why: Trials are how the next standard of care is set; asking early keeps options open.
Would a second opinion at a high-volume centre change anything, and can you help arrange it?
Why: Rare or high-stakes decisions benefit from a centre that treats many similar patients.
What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?
Why: Supportive care improves quality of life and helps patients complete treatment.
I read that “Continuous BTK inhibitor or fixed-duration venetoclax first: no head-to-head survival data”. How does that affect my plan?
Why: Open problems are where trials and second opinions matter most.
I read that “Whether MRD should decide how long fixed-duration therapy lasts”. How does that affect my plan?
Why: Open problems are where trials and second opinions matter most.

Newly diagnosed? Read the first 60 days with Chronic lymphocytic leukaemia, first treatment, then print the one-page appointment sheet with room for the answers.

Print this page for your appointment (your browser's print command). These prompts are for discussion; your clinical team knows your case.

62top

Direct links plus the targets, companies, and technologies of this cancer's products.

Key papers

3top

rctNew England Journal of Medicine 2025changed practice

AMPLIFY: fixed-duration acalabrutinib plus venetoclax, with or without obinutuzumab, versus chemo-immunotherapy in fit CLL patients

AMPLIFY delivered the first all-oral, fixed-duration doublet for front-line CLL and supported its approval, giving fit patients a way to avoid both chemotherapy and years of continuous BTK inhibitor. It does not settle whether a doublet or triplet is best, or how AV compares with venetoclax-obinutuzumab. Patients with TP53 aberration were excluded and still need different strategies.

rctThe Lancet 2020changed practice

ELEVATE-TN: acalabrutinib, alone or with obinutuzumab, against chemo-immunotherapy in untreated CLL

ELEVATE-TN put a more selective BTK inhibitor into first-line CLL and, with the head-to-head ELEVATE-RR trial, showed it is as effective as ibrutinib with fewer cardiac side effects. Continuous acalabrutinib became one of the two main front-line options alongside fixed-duration venetoclax combinations. The trade-off is indefinite therapy and cost versus a time-limited course.

rctNew England Journal of Medicine 2019changed practice

CLL14: one year of venetoclax plus obinutuzumab instead of chemo-immunotherapy in older, less fit CLL patients

CLL14 established the first chemotherapy-free, fixed-duration regimen for front-line CLL and made MRD-guided thinking mainstream in the disease. Patients get a year of treatment and then a treatment-free period rather than indefinite therapy. The choice today is between fixed-duration venetoclax combinations and continuous BTK inhibitors, with no proven survival difference.